- Conditions
- Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
- Interventions
- Everolimus (RAD001), Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
- Interventions
- Bendamustine, Rituximab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Boone, North Carolina • Chapel Hill, North Carolina • Concord, North Carolina + 4 more
- Conditions
- Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
- Interventions
- entinostat, clofarabine, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Denver, Colorado • Baltimore, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- Abrocitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Asthma
- Interventions
- Ciclesonide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Asthma
- Interventions
- Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
- Conditions
- Trauma, Hiv, Aging
- Interventions
- CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging), Control
- Behavioral
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
- Interventions
- Actis Total Hip System
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- Louisville, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Smokers, Elderly, Asthma, COPD, Recurrent Infections
- Interventions
- PPV-23
- Biological
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Asthma
- Interventions
- Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Talquetamab, Daratumumab
- Drug
- Lead sponsor
- Larysa Sanchez
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
- Interventions
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Other
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 2,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Ofatumumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 66 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cognitive Impairment, Dementia, Mild, Cognitive Decline
- Interventions
- RACS app
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- HIV/AIDS, Chronic Pain
- Interventions
- Acceptance and Commitment Therapy (ACT), Chronic Pain Education
- Behavioral · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
- Conditions
- Asthma
- Interventions
- Fluticasone Furoate, Fluticasone Propionate, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
- Interventions
- voriconazole
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 11 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Orange, California • San Diego, California • Bethesda, Maryland + 4 more
- Conditions
- Hepatitis B
- Interventions
- HEPLISAV
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CDOP plus rituximab
- Drug
- Lead sponsor
- Geriatric Oncology Consortium
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 5
- States / cities
- Oxnard, California • Washington D.C., District of Columbia • Inverness, Florida + 2 more
- Conditions
- Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Interventions
- Ublituximab
- Drug
- Lead sponsor
- Neurology Center of New England P.C.
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Foxborough, Massachusetts